CAR T cell therapy study for children with DIPG brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 26 years old and weigh at least 10 kg (about 22 pounds).
- You have been diagnosed with DIPG based on brain scans, with or without a biopsy.
- You have finished standard radiation therapy within the last 6 weeks.
- You have a special catheter in your brain to deliver the study drug.
- You are able to have a procedure to collect your white blood cells (leukapheresis).
- You are generally healthy enough to participate, with stable or improving symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.